second-generation anti-BCMA CAR T-cell therapy (Universidad de Sevilla)

N/A

Report date: 2025/06/11 11:07:18

Base Information

Drug Namesecond-generation anti-BCMA CAR T-cell therapy (Universidad de Sevilla)

Drug Alias Nameanti-BCMA CAR T-cell therapy (Universidad de Sevilla)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsTumor necrosis factor ligand superfamily member 13 modulatorsT lymphocytes stimulants

TargetsTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversidad de Sevilla

China Registration ClassN/A

Develop Information

Active CompaniesUniversidad de Sevilla

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A